Myoferlin is a novel protein of unknown function with high homology to dysferlin, the gene mutations of which cause limb girdle muscular dystrophy type 2B and Miyoshi myopathy. The myoferlin gene seems to be a candidate for the modifier, and because of the high homology to dysferlin myoferlin may work as a compensator for the absence of dysferlin in dysferlinopathy. This hypothesis is based on the observation that utrophin, which has 80% homology with dystrophin, is overexpressing in the dystrophin deficient myofibers. To test this hypothesis, we investigated the myoferlin expression by immunoblot and immunohistochemical analysis in muscles of five patients with dysferlinopathy. For this aim, we generated a myoferlin specific antibody that does not cross react with dysferlin, and performed the immunoblot, immunohistochemical and immunoelectron microscopic studies. Immunohistochemical analysis showed that the antibodies against myoferlin and dysferlin clearly stained the normal human myofiber surface membranes. The electron microscopy of single immunogold labeled samples for myoferlin showed the presence of the molecular signal along the normal muscle cell membrane. Immunoblot analysis showed that the intensity of 230-kDa myoferlin band of dysferlinopathy muscle extracts was similar to that of normal muscle extracts. The immunostaining of dysferlinopathy muscles with anti-myoferlin antibody revealed a weak immunoreactivity along the muscle cell surface. Thus, the compensatory overexpression of myoferlin was not detected in muscles with dysferlinopathy. myoferlin; dysferlin; limb girdle muscular dystrophy type 2B; miyoshi myopathy
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The dysferlin gene encodes a novel protein of 230 kDa with a single transmembrane domain, and mutations in the dysferlin gene have recently been identified in patients with limb girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi type distal muscular dystrophy (Miyoshi myopathy [MM] ) (Bashir et al. 1998; Liu et al. 1998) . The function of dysferlin is unknown, but dysferlin is highly homologous to fer-1, a Caenorhabditis elegans protein necessary for fusion of the membranous organelle to the sperm plasma membrane (Argon and Wads 1980; Ward et al. 1981; Achanzar and Ward 1997) . Humans with mutations in the dysferlin gene develop muscle weakness that affects both proximal (LGMD2B) (Mahjneh et al. 1996) and distal (MM) muscles (Miyoshi et al. 1986 ), however, this phenotypic variability cannot be explained by the type of mutation in the dysferlin gene. Dysferlin is thought to be a type 2 transmembrane protein with a predicted topology that places most of the molecule within the cytoplasm anchored by its C-terminal transmembrane domain. Dysferlin contains six C2 domains, which are independently folding domains found in many proteins involved in signal transduction and membrane trafficking (Coussens et al. 1986; Knopf et al. 1986; Perin et al. 1990; Rizo and Sudhof 1998) . C2 domains bind Ca 2+ , phospholipids and lipid bilayers (Davletov and Sudhof 1993) in addition to other proteins in Ca
2+
-dependent and -independent manners (Li et al. 1995) .
Myoferlin, a protein highly homologous to dysferlin, was identified through electronic database searching (Davis et al. 2000) . Myoferlin is nearly identical in size to dysferlin and is predicted to be a type 2 transmembrane protein with a large cytoplasmic domain containing six C2 domains and a single C-terminal membranespanning domain. We hypothesized that myoferlin is a candidate gene for muscular dystrophy and cardiomyopathy, or possibly a modifier of the muscular dystrophy phenotype (Davis et al. 2000) . Furthermore, we are interested in the expression of myoferlin in muscles with dysferlinopathy and we are especially interested with respect to whether the increased expression of myoferlin is present in these muscles. This idea is based on the observation that utrophin, which has 80% homology with dystrophin, is overexpressed in the dystrophin deficient myofibers (Takemitsu et al. 1993) . In this study, we generated a myoferlin specific antibody that does not cross react with dysferlin, and investigated the expression and localization of myoferlin in normal skeletal myofiber by immunoblot, immunohistochemical and immunoelectron microscopic analysis. To test this hypothesis, we examined the expression of myoferlin in the biopsied muscles of patients with dysferlinopathy by immunoblot and immunohistochemical analysis.
MATERIALS AND METHODS

Muscle samples
Five histochemically normal human quadriceps femoris muscles were obtained from patients who were deemed to have myopathy, but were found to be free of neuromuscular diseases after the full battery of histochemical examinations. The diagnosis of dysferlinopathy was performed on the basis of immunoblot analysis and immunohistochemistry of the biopsied muscles from the patients with limb girdle muscular dystrophy and distal muscular dystrophy by using the mouse monoclonal anti-dysferlin antibody (NCL hamlet, Novocastra, Newcastle Upon Tyne, UK). The muscles with dysferlinopathy were biopsied from three patients with LGMD2B (patient No. 1, 2, 3) and from two patients with MM (patient No. 4, 5). All muscle samples were taken under informed consent. The procedure of muscle biopsy was approved by the ethics committee of Showa University.
Peptide synthesis and antibody production
General procedures for myoferlin peptide synthesis and antibody generation are similar to those described previously (Wakayama et al. 1990 ). In brief, the synthetic peptide of the cytoplasmic domain of myoferlin was deduced from amino acid residues 928-945 (C-TEFTDEVYQNESRYPGGD). This region contains no significant homology to dysferlin or otoferlin (Bashir et al. 1998; Liu et al. 1998 ). The extra cysteine residue was added to the N-terminus of this peptide for conjugation with bovine thyroglobulin. The antibody against this peptide was generated in rabbit. Solid-phase enzyme-linked immunosorbent assay was performed to determine the rabbit polyclonal antibody titer, which was × 204,800. The mouse monoclonal anti-dysferlin antibody (NCL hamlet) was purchased from Novocastra (New Castle Upon Tyne, UK). In addition, we generated a rabbit polyclonal anti-dysferlin antibody against the dysferlin specific synthetic peptide (dysferlin amino acid residue 971-987: C-NYTDVNGEKVLPKDDIE). The skeletal muscle specific anti-spectrin antibody was previously generated in our laboratory (Winkelmann et al. 1990; Porter et al. 1992; Wakayama et al. 1995) . The primary antibodies used in this study are summarized in Table 1 .
Immunoblot analyses of anti-myoferlin and anti-dysferlin antibodies
Immunoblot analyses of rabbit anti-myoferlin, dysferlin and β -spectrin antisera in the human normal quadriceps femoris muscles and muscles with dysferlinopathy were performed using a previously described method (Wakayama et al. 1990 ) with minor modifications. Sodium dodecyl sulfate-polyacrylamide gel electrophoreses for myoferlin and dysferlin were performed on 3~10% gradient gel. The proteins were transferred from the gel to a clear-blot P membrane (ATTO, Tokyo) sheet by horizontal electrophoresis at 108 mA for 90 min at room temperature.
Immunohistochemistry
For immunohistochemical analysis, the excised five histochemically normal human quadriceps femoris muscles and five muscles with dysferlinopathy were frozen immediately in isopentane cooled by liquid nitrogen. Frozen 6-μ m cross-sections of all the muscles were placed on cover slips and incubated with primary rabbit anti-myoferlin antibody (antiserum) diluted 1 : 100. The muscles with dysferlinopathy were similarly processed with primary mouse monoclonal anti-dysferlin antibody (NCL-hamlet), our polyclonal anti-dysferlin specific antibody (antiserum) and skeletal muscle specific antispectrin antibody (antiserum). The dilution titers of the primary antibodies are shown in Table 1 . Indirect immunofluorescent staining was performed according to the methods previously described (Wakayama et al. 1990 ).
Immunoelectron microscopy
Single-immunogold labeled electron microscopic examinations were performed. First, five histochemically normal human quadriceps femoris muscles were put in a U-shaped muscle clamp and immersed for fixation in chilled 4% paraformaldehyde solution in 0.1 M phosphate buffer (pH 7.4) for 1 hr. The fixed muscles were washed four times in phosphate-buffered saline (PBS) and frozen in liquid nitrogen-cooled isopentane. The muscles were then cut in a cryostat into thin sections and washed thoroughly in PBS. To eliminate nonspecific reactions, the sections were incubated for 30 min at room temperature in PBS containing 5% normal goat serum for single immunolabeling. For immunolabeling, 1 : 100 diluted rabbit polyclonal anti-myoferlin antibody was used and was applied to sections for 24 hrs at 4°C. After thorough rinsing, the secondary antibody, 5-nm goldlabeled goat anti-rabbit antibody (Amersham, Arlington Heights, Ill) was diluted 1 : 20 in PBS. Diluted secondary antibody was applied to sections for 24 hrs at 4°C, which was then washed four times. Immunocontrol sections were incubated with nonimmune rabbit serum instead of the primary antibody. The antibody labeled and immunocontrol muscle samples were further fixed in chilled 2.5% glutaraldehyde solution in 0.1 M phosphate buffer (pH 7.4) for 30 min. These samples were postfixed in chilled 2% O S O 4 solution for 1 hr, dehydrated in an ascending series of ethanol and propylene oxide, and embedded in Epon. The unstained ultrathin sections were examined using a Hitachi H7000 electron microscope (Hitachi, Tokyo). 
RESULTS
Immunoblot analyses
Immunoblot analysis showed that rabbit antibody against synthetic peptide of myoferlin (left lane in Fig. 1A and lane C in Fig. 1B ) and rabbit polyclonal anti-dysferlin antibody (lane C in Fig. 1B ) reacted with 230-kDa protein in human normal muscle extracts. In contrast, immunoblot analysis using immunodepleted antibody solution did not reveal this band (right lane in Fig. 1A) . The extracts of five muscles with dysferlinopathy revealed a slightly weak band with anti-myoferlin antibody and no band with rabbit polyclonal anti-dysferlin antibody (lane 1-5 in Fig. 1B) , in immunoblotting. None of the extracts of five muscles with dysferlinopathy showed a compensatory intense staining band with anti-myoferlin antibody.
Immunohistochemistry and immunoelectron microscopy of normal muscles
Immunohistochemical analysis showed that the antibodies against myoferlin and dysferlin strongly and clearly stained the cross-sectioned normal human myofiber surface membrane (Fig.  2 A and B) . The electron microscopy of single immunogold labeled samples for myoferlin showed the presence of the molecular signal along the muscle cell membrane (Fig. 3 A and B) . The costameric distribution of the molecule was not obvious, but in some instances, it was suggestive. Immunocontrol muscle samples contained no gold particles (data not shown). 
Immunohistochemistry of muscles with dysferlinopathy
The immunostaining of dysferlinopathy muscles with rabbit polyclonal anti-myoferlin antibody revealed an immunoreaction with a weak immunoreactivity along the muscle cell surface (Fig. 4A) as compared with the immunostaining of the serial muscle sections with anti-β -spectrin antibody (Fig. 4B) . The immunostaining of the serial sections of muscles by rabbit polyclonal anti-dysferlin specific antibody and mouse monoclonal anti-dysferlin antibody (NCLhamlet) showed very weak to negative immunostaining at the muscle cell surface (Figs. 4C and  4D ). Davis et al. (2000) reported the isolation and characterization of a novel protein, myoferlin which is a protein with 230 kDa molecular weight and is highly homologous to dysferlin (Bashir et al. 1998; Liu et al. 1998 ) over nearly its entire length. Both proteins appear to be type II transmembrane proteins with a single transmembrane domain very near to the C-terminus of the protein.
DISCUSSION
The predicted topology of both proteins indicates that the majority portion of the protein is present in the sarcoplasm (Davis et al. 2000) . The immunoelectron microscopic analysis using our antimyoferlin antibody revealed that most of the signals of myoferlin localized at the inside surface of the normal skeletal myofiber. The results demonstrate that the predicted portion of the myoferlin was present in the sarcoplasm (Davis et al. 2000) . Although the roles of myoferlin at the muscle cell surface are unknown, several putative functions have been proposed. First is a function of signal transduction or membrane trafficking, since myoferlin has six C2 domains, which are found in proteins involved in such function. Second is a role for myoferlin in the myoblast fusion during embryonic development (Doherty et al. 2005) or membrane repair of myofiber as regeneration; C2 domains of myoferlin have also been shown to bind phospholipids (Davletov and Sudhof 1993) and consequently membrane fusion occurs. Third is that C2 domains of myoferlin are also known to bind other proteins in calcium-dependent and -independent manners (Pardo et al. 1983; Zhang et al. 1994; Li et al. 1995; Schiavo et al. 1995; Sheng et al. 1997 ).
The myoferlin gene seems to be a candidate gene for the modifier, and because of the high homology to dysferlin myoferlin may work as a compensator for the absence of dysferlin. It is tempting to speculate that different clinical phenotypes such as LGMD2B and MM arise from mutations in the same dysferlin gene. Mutation analysis of dysferlin gene revealed nonsense, missense and frameshifting mutations with LGMD2B and MM and identical mutation in patients with LGMD2B and MM, which indicates a role for modifier gene(s) (Weiler et al. 1999) . In other words, genetic modifiers may play a role in mediating the severity of the phenotype and the muscle groups affected in the absence of dysferlin (Weiler et al. 1999) . In order to test this hypothesis, we generated a specific antibody against myoferlin in which the amino acids of synthetic peptide were quite different from those of dysferlin (Bashir et al. 1998) . The immunoreactivity of this antimyoferlin antibody in the muscles with dysferlin deficiency showed slightly weak intensity, although the immunoreactivity of monoclonal anti-dysferlin antibody was markedly reduced. Thus, the compensatory overexpression of myoferlin was not detected in muscles with dysferlinopathy. Further studies will throw light into the functional role of myoferlin in the pathogenesis of dysferlinopathy.
